Impact of Frozen-thawed Embryo Transfers and Hormone Substitution on Thrombotic Risk Markers
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Frozen Embryo Transfer
- Sponsor
- Horsens Hospital
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- coagulation
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
The study focus on the impact of estrogen/progesterone substitution during artificial cycle frozen embryo transfer (AC-FET) in women undertaking assisted reproductive technology treatment (ART).
Detailed Description
The aim is to investigate whether the coagulation is activated in women undergoing estrogen/progesterone substitution during artificial cycle frozen embryo transfer (AC-FET) in assisted reproductive technology treatment (ART). An activation of the coagulation might induce an increased thromboembolic risk in these women. Thus, the present study may lead to improvement of the current treatment protocol for women receiving AC-FET and ultimately prevent thromboembolic complications for woman in fertility treatment.
Investigators
Ulla Breth Knudsen
Professor
Horsens Hospital
Eligibility Criteria
Inclusion Criteria
- •Women receiving FET with or without estrogen/progesterone substitution
Exclusion Criteria
- •Known bleeding disorder
- •Indication for thromboprophylaxis during ART treatment
- •Treatment with anti-platelet medication including non-steroid-anti-inflammatory drugs (NSAIDs) within the last week
- •Donor recipients
Outcomes
Primary Outcomes
coagulation
Time Frame: 1 year
Primary and secondary hemostasis parameters